 The FDA has placed a partial clinical hold on Bluebird bio Incs NASDAQ: BLUE lovotibeglogene autotemcel lovo-cel gene therapy program for sickle cell disease SCD for patients under the age of 18. The partial, temporary suspension relates to an ongoing investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, now 18 months post-treatment. 